Compare DAIO & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DAIO | GRML |
|---|---|---|
| Founded | 1969 | N/A |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Electrical Products | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.2M | 34.9M |
| IPO Year | 2026 | 2022 |
| Metric | DAIO | GRML |
|---|---|---|
| Price | $3.17 | $0.19 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.22 | N/A |
| AVG Volume (30 Days) | 38.4K | ★ 7.4M |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $21,500,000.00 | N/A |
| Revenue This Year | $4.51 | N/A |
| Revenue Next Year | $30.29 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.16 | $0.16 |
| 52 Week High | $4.49 | $0.55 |
| Indicator | DAIO | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 37.55 | 40.29 |
| Support Level | $2.60 | $0.16 |
| Resistance Level | $3.26 | $0.30 |
| Average True Range (ATR) | 0.19 | 0.03 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 29.31 | 8.03 |
Data I/O Corp provides semiconductor programming, security provisioning, and intellectual property protection and management solutions used in electronics manufacturing with flash memory, microcontrollers, and flash memory-based intelligent devices as well as secure element devices, authentication devices and secure microcontrollers. It operates as a single segment entity, with the sole objective to design, manufacture, and sell programming solutions and Programming-as-a-Service (PaaS) to the world's various electronics manufacturers including OEMs, CMs and EMS companies. The company operate in three separate locations Redmond, Washington; Shanghai, China; and Munich, Germany.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.